Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug hepatotoxicity.

Rahul A Nathwani1, Neil Kaplowitz

  • 1Division of Gastrointestinal and Liver Disease, Department of Medicine, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, HMR 101, Los Angeles, CA 90033, USA.

Clinics in Liver Disease
|September 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a United Arab Emirates national inflammatory bowel disease transition care pathway: Findings from a healthcare professional survey and development of evidence-based tools.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association·2026
Same author

Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.

World journal of gastroenterology·2025
Same author

Bile acids in liver and gastrointestinal cancer.

Seminars in cancer biology·2025
Same author

Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure.

Clinical and molecular hepatology·2025
Same author

Hepatic LRP-1 plays an important role in amyloidosis in Alzheimer's disease mice: Potential role in chronic heavy alcohol feeding.

Neurobiology of disease·2024
Same author

Mitochondrial P-JNK target, SAB (SH3BP5), in regulation of cell death.

Frontiers in cell and developmental biology·2024
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Drug-induced liver injury is a growing concern. This review discusses controversial management strategies for drug-induced liver injury, including anti-tuberculosis therapy, liver monitoring, steroid use, and ursodeoxycholic acid for cholestasis.

Area of Science:

  • Hepatology
  • Clinical Pharmacology

Background:

  • Drug-induced liver injury (DILI) is an increasingly recognized cause of liver disease.
  • Accurate diagnosis and management of DILI remain challenging, particularly in specific clinical scenarios.

Purpose of the Study:

  • To review and provide recommendations on controversial aspects of DILI management.
  • To address the use of anti-tuberculosis therapy in patients with cirrhosis and DILI.
  • To evaluate the role of liver monitoring, steroid therapy, and ursodeoxycholic acid in DILI.

Main Methods:

  • Literature review and expert opinion synthesis.
  • Analysis of current evidence regarding DILI and specific therapeutic interventions.

Main Results:

Related Experiment Videos

  • Discussion on the risks and benefits of anti-tuberculosis therapy in cirrhotic patients with DILI.
  • Evaluation of the utility of periodic liver tests and steroid therapy in DILI cases.
  • Exploration of class effects of drugs and the potential of ursodeoxycholic acid in cholestatic DILI.

    • Conclusions:

    • Controversial DILI management strategies require careful consideration of individual patient factors and available evidence.
    • Further research is needed to clarify optimal approaches for specific DILI presentations and treatments.